|
rs1064793998
|
|
|
0.720 |
GeneticVariation |
BEFREE |
The glucokinase V62M and G72R mutations are naturally occurring and known to associate with hyperglycemia in humans.
|
19187021 |
2009 |
|
rs1064793998
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We conclude that V62M may cause hyperglycemia by a complex defect of GCK regulation involving instability in combination with loss of control by a putative endogenous activator and/or GKRP.
|
15677479 |
2005 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Diabetes-associated variation (T allele at rs7903146) in TCF7L2 may impair the ability of hyperglycemia to suppress glucagon (45 ± 2 vs. 47 ± 2 vs. 60 ± 5 ng/L for CC, CT, and TT, respectively, P = 0.02).
|
22461567 |
2012 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).
|
18853134 |
2008 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Also the well-known gene variants rs7903146 in TCF7L2, and rs17817449 in FTO, were nominally associated with hyperglycemia (rs7903146), as well as with higher fasting insulin levels (rs17817449).
|
30063936 |
2018 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We conclude that the TCF7L2 T at-risk allele variation (rs7903146) predicts hyperglycemia incidence in a general French population, possibly through a deleterious effect on insulin secretion.
|
17065361 |
2006 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The T-allele of TCF7L2 rs7903146 polymorphism was independently associated with increasing fasting glucose values toward hyperglycemia in the follow-up.
|
20299486 |
2010 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
There were significant linear interactions between rs7903146 and BMI/WC and elevated blood glucose (P < 0.001); rs290487 and BMI/WC also showed a linear interaction with blood glucose levels (P < 0.001).
|
30718095 |
2020 |
|
rs7903146
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We confirmed that the risk allele of rs7903146 is associated with hyperglycaemia and a higher proinsulin/insulin ratio.
|
19183934 |
2009 |
|
rs1799983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The eNOS G894T polymorphism appears to be predictive of persistent hyperglycemia in Chinese subjects with IGT.
|
16919532 |
2006 |
|
rs1799983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Effects of human endothelial gene polymorphisms on cellular responses to hyperglycaemia: role of NOS3 (Glu298Asp) and ACE (I/D) polymorphisms.
|
21844127 |
2011 |
|
rs1801282
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Genotyping for Pro12Ala and Trp64Arg polymorphism in postmenopausal women may have the clinical benefit of predicting hyperglycaemia, thereby contributing to the prevention of diabetes mellitus development in the future.
|
29464546 |
2018 |
|
rs1801282
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The combined effects of PPARG Pro12Ala and APM1 G-11391A SNPs showed no interaction on the risk of 6-year hyperglycemia.
|
16567542 |
2006 |
|
rs1805192
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Genotyping for Pro12Ala and Trp64Arg polymorphism in postmenopausal women may have the clinical benefit of predicting hyperglycaemia, thereby contributing to the prevention of diabetes mellitus development in the future.
|
29464546 |
2018 |
|
rs1805192
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The combined effects of PPARG Pro12Ala and APM1 G-11391A SNPs showed no interaction on the risk of 6-year hyperglycemia.
|
16567542 |
2006 |
|
rs80356624
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Four of the five patients with mutations had neurological features: the patient with the C166F mutation had marked developmental delay, severe generalised epilepsy, hypotonia and muscle weakness; mild developmental delay was present in the patient with the V59M mutation; one patient with the R201H mutation had acute and chronic neurological consequences of cerebral oedema and another had diabetic neuropathy from chronic hyperglycaemia.
|
16670688 |
2006 |
|
rs80356624
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The R201H mutation was identified in a patient who developed hyperglycemia and ketoacidosis at the age of 40 d and was successfully transferred to sulphonylureas which activate the channel through an ATP independent route.
|
21352428 |
2011 |
|
rs9939609
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The A/A genotype of the <i>FTO</i> rs9939609 polymorphism increases the risk of hyperglycemia, and the C/C genotype of the <i>PPAR-γ</i> rs1801282 variant entails elevated blood pressure in 45-60-year-old women.
|
29315078 |
2018 |
|
rs9939609
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).
|
18853134 |
2008 |
|
rs10010131
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).
|
18853134 |
2008 |
|
rs10139403
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In meta-analysis including additional independent Hyperglycemia and Adverse Pregnancy Outcome Study data, the association with maternally transmitted fetal DLK1 rs10139403 reached genome-wide significance (P=6.3×10<sup>-10</sup>).
|
27777362 |
2016 |
|
rs1018185646
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Five novel (F195S, I211T, V222D, E236G and K458R) and five known (T49N, I159V, R186X, A188T and M381T) mutations were identified and co-segregated with hyperglycaemia in their pedigrees.
|
30257192 |
2018 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ABCB1 rs1045642 was associated with risk of mucositis (P = 0.031), while PIK3R1 rs10515074 and RAPTOR rs9906827 were associated with hyperglycemia and non-infectious pneumonitis (P = 0.016 and 0.024, respectively).
|
28727815 |
2017 |
|
rs104894006
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Five novel (F195S, I211T, V222D, E236G and K458R) and five known (T49N, I159V, R186X, A188T and M381T) mutations were identified and co-segregated with hyperglycaemia in their pedigrees.
|
30257192 |
2018 |
|
rs1050828
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After recalibration of the HbA<sub>1c</sub> level taking <i>HBB</i>-rs334 and <i>G6PD</i>-rs1050828 into account, the prevalence of hyperglycemia in carriers was similar to noncarriers (31.3% vs. 28.4%, <i>P</i> = 0.28).
|
31213470 |
2019 |